Teva Pharma upgraded by Analyst with a new price target
$TEVA
Biotechnology: Pharmaceutical Preparations
Health Care
Analyst upgraded Teva Pharma from Neutral to Overweight and set a new price target of $23.00
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/6/2025 | $24.00 | Buy | Goldman |
| 5/28/2025 | $25.00 | Buy | Truist |
| 5/12/2025 | $23.00 | Neutral → Overweight | Analyst |
| 7/10/2024 | $20.00 | Hold → Buy | Argus |
| 3/8/2024 | $14.00 | Underweight → Neutral | JP Morgan |
| 2/12/2024 | $12.00 → $19.00 | Neutral → Overweight | Piper Sandler |
| 1/23/2024 | $10.00 → $14.00 | Hold → Buy | Jefferies |
| 1/3/2024 | $8.00 → $12.00 | Underweight → Neutral | Piper Sandler |
TEL AVIV, Israel, June 26, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q2 2025 Aide Memoire is available on the "Investors" page on its website. Q2 2025 Aide Memoire Teva has prepared this document to assist in the financial modeling of its quarterly results. The document is based on Teva's prior results, management's previous commentary about Teva's business outlook and data from select independent sources. About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a different kind of global biopharmaceutical leader, one that operates across the full spectrum of innovation to reliably deliver medicine
USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 26, 2025 /PRNewswire/ -- USA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in cancer-focused biotechs is rapidly intensifying. ResearchAndMarkets and Vision Research Reports both point to strong double-digit growth, citing surging demand for next-gen diagnostics and immunotherapies. Yet even as market potential grows, the U.S. public health sector is facing potential setbacks. Budget proposals suggest National Cancer Institute (NCI) funding could be slashed by up to 40%, while Bloomberg highlights concerns
TEL AVIV, Israel, June 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2025 financial results on Wednesday, July 30, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on Teva's website at: https://ir.tevapharm.com/Events-and-Presentations. Following the conclusion of the call, a replay of the webcast will be available within 24 h
8-K - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Filer)
SD - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Filer)
8-K - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Filer)
Goldman initiated coverage of Teva Pharma with a rating of Buy and set a new price target of $24.00
Truist initiated coverage of Teva Pharma with a rating of Buy and set a new price target of $25.00
Analyst upgraded Teva Pharma from Neutral to Overweight and set a new price target of $23.00
4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 26, 2025 /PRNewswire/ -- USA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in cancer-focused biotechs is rapidly intensifying. ResearchAndMarkets and Vision Research Reports both point to strong double-digit growth, citing surging demand for next-gen diagnostics and immunotherapies. Yet even as market potential grows, the U.S. public health sector is facing potential setbacks. Budget proposals suggest National Cancer Institute (NCI) funding could be slashed by up to 40%, while Bloomberg highlights concerns
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Matthew Shields as Executive Vice President of Teva Global Operations (TGO), the Company's manufacturing and supply division, effective June 3, 2024. Mr. Shields succeeds Eric Drapé, who is leaving after 11 years with the Company, including more than four years as Executive Vice President, Global Operations. Mr. Shields will be a member of Teva's Executive Leadership Team and report directly to President and CEO Richard Francis. He will be based in Teva's U.S. headquarters in Parsippany, NJ. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Dr. R. Ananthanarayanan (Ananth) as CEO of its Teva Active Pharmaceutical Ingredients business (Teva api). Dr. Ananth will lead the API business starting November 27, 2023, and will be based out of Teva's U.S. headquarters in Parsippany, NJ. Richard Francis, Teva's President and CEO said: "I am excited to welcome Ananth back to Teva to lead the Teva api business during this pivotal time for our company, as we continue to progress on our plan for turning Teva api into a standalone business. We're confident that this strategy will result in a more focused end-to-end operation, and I am confident tha
TEL AVIV, Israel, June 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2025 financial results on Wednesday, July 30, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on Teva's website at: https://ir.tevapharm.com/Events-and-Presentations. Following the conclusion of the call, a replay of the webcast will be available within 24 h
For an accessible version of this Press Release, please visit www.tevapharm.com On track for 30% operating profit margin by 2027 in line with our Pivot to Growth Strategy; Q1 2025 shows ninth consecutive quarter of revenue growth, excluding revenues recorded for Sanofi collaboration.Q1 2025 revenues of $3.9 billion, an increase of 5%; net of $100 million foreign exchange impact, reported revenues growth of 2%.AUSTEDO® – shows continued strong growth, with worldwide revenues of $411 million in Q1 2025, an increase of 39% in local currency terms compared to Q1 2024; increasing 2025 full-year revenue outlook from ~$1.9-2.05 billion to $1.95-2.05 billion.AJOVY® – global revenues of $139 million
TEL AVIV, Israel, May 07, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will host Innovation & Strategy Day on Thursday, May 29, 2025 to discuss the acceleration phase of its strategy and portfolio priorities. The event will take place in New York, N.Y. Presentations will begin at 8:30 a.m. Eastern Time and are expected to conclude at 12:30 p.m. Eastern Time. Richard Francis, Teva's President and CEO, along with other members of the executive management team will discuss an update on the strategy and key priorities focusing on growth and innovation. Due to limited capacity, in-person attendance is by invitation only. Analysts a
SC 13G - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)
SC 13G/A - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)
SC 13G - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)